JP2004509601A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509601A5
JP2004509601A5 JP2000539149A JP2000539149A JP2004509601A5 JP 2004509601 A5 JP2004509601 A5 JP 2004509601A5 JP 2000539149 A JP2000539149 A JP 2000539149A JP 2000539149 A JP2000539149 A JP 2000539149A JP 2004509601 A5 JP2004509601 A5 JP 2004509601A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
hiv
molecule according
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000539149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509601A (ja
Filing date
Publication date
Priority claimed from US08/991,773 external-priority patent/US6121021A/en
Application filed filed Critical
Publication of JP2004509601A publication Critical patent/JP2004509601A/ja
Publication of JP2004509601A5 publication Critical patent/JP2004509601A5/ja
Pending legal-status Critical Current

Links

JP2000539149A 1997-12-16 1998-12-14 非感染性hiv様粒子の組換え発現 Pending JP2004509601A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/991,773 US6121021A (en) 1997-12-16 1997-12-16 Constitutive expression of non-infectious HIV-like particles
PCT/CA1998/001164 WO1999031250A2 (en) 1997-12-16 1998-12-14 Constitutive expression of non-infectious hiv-like particles

Publications (2)

Publication Number Publication Date
JP2004509601A JP2004509601A (ja) 2004-04-02
JP2004509601A5 true JP2004509601A5 (cg-RX-API-DMAC7.html) 2004-12-24

Family

ID=25537545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539149A Pending JP2004509601A (ja) 1997-12-16 1998-12-14 非感染性hiv様粒子の組換え発現

Country Status (12)

Country Link
US (2) US6121021A (cg-RX-API-DMAC7.html)
EP (1) EP1038001B8 (cg-RX-API-DMAC7.html)
JP (1) JP2004509601A (cg-RX-API-DMAC7.html)
AT (1) ATE318909T1 (cg-RX-API-DMAC7.html)
AU (1) AU749174B2 (cg-RX-API-DMAC7.html)
BR (1) BR9813626A (cg-RX-API-DMAC7.html)
CA (1) CA2312943C (cg-RX-API-DMAC7.html)
DE (1) DE69833686T2 (cg-RX-API-DMAC7.html)
DK (1) DK1038001T3 (cg-RX-API-DMAC7.html)
ES (1) ES2262250T3 (cg-RX-API-DMAC7.html)
PT (1) PT1038001E (cg-RX-API-DMAC7.html)
WO (1) WO1999031250A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
EP2388015A1 (en) 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
EP1280551B1 (en) * 2000-04-27 2007-01-10 Sanofi Pasteur Limited Vaccines against hiv infection
EP1776961A1 (en) * 2000-04-27 2007-04-25 Sanofi Pasteur Limited Immunizing against HIV infection
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
EP2055316A1 (en) * 2003-09-09 2009-05-06 VIRxSYS Corporation Lentivirus vector-based approaches for generating an immune response to HIV in humans
US20090257983A1 (en) * 2008-04-11 2009-10-15 Scheiber Lane Bernard Medical treatment device for treating aids by utilizing modified human immunodeficiency virus virions to insert anti-viral medications into t-helper cells
US20110293693A1 (en) * 2010-05-31 2011-12-01 Scheiber Lane Bernard Quantum unit of inheritance vector therapy
US20110293694A1 (en) * 2010-05-31 2011-12-01 Scheiber Lane Bernard Quantum unit of inheritance vector therapy method
EP3173096A1 (en) 2011-04-06 2017-05-31 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
CA2067778A1 (en) * 1989-10-16 1991-04-17 The Whitehead Institute For Biomedical Research Non-infectious hiv-1 particles and uses therefor
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
JP3494300B2 (ja) 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Hivに対する予防接種のための方法および組成物
JPH08500005A (ja) * 1992-03-27 1996-01-09 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 非感染性hiv粒子およびその用途
CA2164505A1 (en) * 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
KR960703136A (ko) * 1993-06-09 1996-06-19 미첼 클레인 탠덤 합성 hiv-1 펩티드들
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
AU725143B2 (en) * 1996-10-17 2000-10-05 Oxford Biomedica (Uk) Limited Retroviral vectors
JP4312265B2 (ja) * 1997-04-09 2009-08-12 ラング−ジ チャン ワクチン評価のための動物モデル
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles

Similar Documents

Publication Publication Date Title
JP2004509601A5 (cg-RX-API-DMAC7.html)
US5773260A (en) Ribozyme compositions and expression vectors
JP2004508808A5 (cg-RX-API-DMAC7.html)
JP2001502539A (ja) レトロウイルスベクター
JP2002503477A5 (cg-RX-API-DMAC7.html)
AU3762889A (en) Hiv-3 retrovirus and its use
EP0817854A2 (en) Antigen presentation system based on retrovirus-like particles
WO1996021007A2 (en) Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
JP2002533124A5 (cg-RX-API-DMAC7.html)
NO921969L (no) Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener
KR940019314A (ko) 인체면역결핍 바이어스(hiv) 억제 안티센스 서열 및 그밖의 다른 뉴클레오타이드 서열을 함유하는 발현 작제물, 레트로바이러스성 벡터 및 이를 함유하는 재조합 레트로바이러스
HU9600587D0 (en) Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains
JP3453611B2 (ja) ハイブリッド形態の新規可溶性、非開裂性gp160変異体
WO2001046408A2 (en) Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
JP2003517839A5 (cg-RX-API-DMAC7.html)
WO2012118092A1 (ja) 融合タンパク質
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.
WO2002003917A3 (en) Alphavirus vectors and virosomes with modified hiv genes for use as vaccines
Kingsman et al. Retroelement particles as purification, presentation and targeting vehicles
JP2010517555A (ja) タンパク質をレンチウイルスベクターに組み込む方法
JP2002513546A5 (cg-RX-API-DMAC7.html)
CA2330618A1 (en) Viral chimeras comprised of caev and hiv-1 genetic elements
CA2325345A1 (en) Medicaments for inducing cytotoxic t-cells
US5707864A (en) Nucleic acids encoding mutated human immunodeficiency virus matrix proteins
Skoging-Nyberg et al. A conserved leucine in the cytoplasmic domain of the Semliki Forest virus spike protein is important for budding